{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:50:57Z","timestamp":1792752657513,"version":"4.5.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/nrmicro1816","type":"journal-article","created":{"date-parts":[[2007,12,14]],"date-time":"2007-12-14T09:44:39Z","timestamp":1197625479000},"page":"41-52","source":"Crossref","is-referenced-by-count":214,"title":["Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis"],"prefix":"10.1038","volume":"6","author":[{"given":"James C.","family":"Sacchettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrmicro1816_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrmicro1065","volume":"3","author":"HIM Boshoff","year":"2005","unstructured":"Boshoff, H. I. M. & Barry 3rd, C. E. Tuberculosis-metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70\u201380 (2005).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro1816_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrmicro1538","volume":"5","author":"DG Russell","year":"2007","unstructured":"Russell, D. G. Who puts the tubercle in tuberculosis? Nature Rev. Microbiol. 5, 39\u201347 (2007).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro1816_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrmicro749","volume":"1","author":"GR Stewart","year":"2003","unstructured":"Stewart, G. R., Roberston, B. D. & Young, D. B. Tuberculosis: a problem with persistence. Nature Rev. Microbiol. 1, 97\u2013105 (2003). Focuses on the biology of persistence in mycobacteria.","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrmicro1816_CR4","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.bmc.2007.01.030","volume":"15","author":"YL Janin","year":"2007","unstructured":"Janin, Y. L. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479\u20132513 (2007). Discusses antitubercular small molecules, from early discovery compounds to approved drugs.","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrmicro1816_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nm0307-290","volume":"13","author":"AM Ginsberg","year":"2007","unstructured":"Ginsberg, A. M. & Spigelman, M. Challenges in tuberculosis drug research and development. Nature Med. 13, 290\u2013294 (2007). An enlightening discussion of the current hurdles in TB drug discovery.","journal-title":"Nature Med."},{"key":"BFnrmicro1816_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/156652407780598575","volume":"7","author":"KJ Williams","year":"2007","unstructured":"Williams, K. J. & Duncan, K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr. Mol. Med. 7, 297\u2013307 (2007). An informative exposition that focuses on drug-discovery strategies.","journal-title":"Curr. Mol. Med."},{"key":"BFnrmicro1816_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro1816_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt1273","volume":"25","author":"AC Cheng","year":"2007","unstructured":"Cheng, A. C. et al. Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnol. 25, 71\u201375 (2007).","journal-title":"Nature Biotechnol."},{"key":"BFnrmicro1816_CR9","doi-asserted-by":"publisher","first-page":"40174","DOI":"10.1074\/jbc.M406796200","volume":"279","author":"HIM Boshoff","year":"2004","unstructured":"Boshoff, H. I. M. et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism. J. Biol. Chem. 279, 40174\u201340184 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro1816_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223\u2013227 (2005).","journal-title":"Science"},{"key":"BFnrmicro1816_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431\u2013436 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2958.1999.01593.x","volume":"34","author":"LR Camacho","year":"1999","unstructured":"Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B. & Guilhot, C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34, 257\u2013267 (1999).","journal-title":"Mol. Microbiol."},{"key":"BFnrmicro1816_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/47042","volume":"402","author":"JS Cox","year":"1999","unstructured":"Cox, J. S., Chen, B., McNeil, M. & Jacobs, W. R. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79\u201383 (1999).","journal-title":"Nature"},{"key":"BFnrmicro1816_CR14","doi-asserted-by":"publisher","first-page":"12712","DOI":"10.1073\/pnas.231275498","volume":"2001","author":"CM Sassetti","year":"2001","unstructured":"Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl Acad. Sci. USA 2001, 12712\u201312717 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR15","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1073\/pnas.1231432100","volume":"12","author":"G Lamichane","year":"2003","unstructured":"Lamichane, G. et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 12, 7213\u20137218 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR16","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1093\/nar\/gni013","volume":"33","author":"S Ehrt","year":"2005","unstructured":"Ehrt, S. et al. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33, e21 (2005).","journal-title":"Nucleic Acids Res."},{"key":"BFnrmicro1816_CR17","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1128\/AEM.71.6.3077-3084.2005","volume":"71","author":"P Carroll","year":"2005","unstructured":"Carroll, P., Muttucumaru, D. G. & Parish, T. Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl. Environ. Microbiol. 71, 3077\u20133084 (2005).","journal-title":"Appl. Environ. Microbiol."},{"key":"BFnrmicro1816_CR18","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1093\/nar\/gni023","volume":"33","author":"MC Blokpoel","year":"2005","unstructured":"Blokpoel, M. C. et al. Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res. 33, e22 (2005).","journal-title":"Nucleic Acids Res."},{"key":"BFnrmicro1816_CR19","doi-asserted-by":"publisher","first-page":"13947","DOI":"10.1021\/bi061874m","volume":"45","author":"A Argyrou","year":"2006","unstructured":"Argyrou, A., Jin, L., Siconilfi-Baez, L., Angeletti, R. H. & Blanchard, J. S. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 45, 13947\u201313953 (2006).","journal-title":"Biochemistry"},{"key":"BFnrmicro1816_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nsmb1089","volume":"13","author":"A Argyrou","year":"2006","unstructured":"Argyrou, A., Vetting, M. W., Aladegbami, B. & Blanchard, J. S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nature Struct. Mol. Biol. 13, 408\u2013413 (2006).","journal-title":"Nature Struct. Mol. Biol."},{"key":"BFnrmicro1816_CR21","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1128\/JB.181.21.6814-6821.1999","volume":"181","author":"V Nopponpunth","year":"1999","unstructured":"Nopponpunth, V., Sirawaraporn, W., Greene, P. J. & Santi, D. V. Cloning and expresion of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J. Bacteriol. 181, 6814\u20136821 (1999).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro1816_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2958.2004.04120.x","volume":"53","author":"J Rengarajan","year":"2004","unstructured":"Rengarajan, J. et al. The folate pathway is a target for resistance to the drug para-aminosalicyclic acid (PAS) in mycobacteria. Mol. Microbiol. 53, 275\u2013282 (2004).","journal-title":"Mol. Microbiol."},{"key":"BFnrmicro1816_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm1466","volume":"12","author":"C Vilcheze","year":"2006","unstructured":"Vilcheze, C. et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nature Med. 12, 1027\u20131029 (2006).","journal-title":"Nature Med."},{"key":"BFnrmicro1816_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nature03193","volume":"432","author":"C Lipinski","year":"2004","unstructured":"Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855\u2013861 (2004).","journal-title":"Nature"},{"key":"BFnrmicro1816_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nrd2144","volume":"5","author":"S Nwaka","year":"2006","unstructured":"Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nature Rev. Drug Discov. 5, 941\u2013955 (2006).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro1816_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/cc020071p","volume":"5","author":"RE Lee","year":"2003","unstructured":"Lee, R. E. et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172\u2013187 (2003). Demonstrates a combinatorial chemistry expansion around ethambutol that was paired with a functional-assay approach to produce novel chemical entities that modulate mycobacterial cell-wall biosynthesis, including SQ109.","journal-title":"J. Comb. Chem."},{"key":"BFnrmicro1816_CR27","first-page":"29","volume":"9","author":"DE Johnson","year":"2006","unstructured":"Johnson, D. E. & Rodgers, A. D. Computational toxicology: heading toward more relevance in drug discovery and development. Curr. Opin. Drug Discov. Devel. 9, 29\u201337 (2006).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnrmicro1816_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2174\/1568026013395074","volume":"1","author":"GM Pearl","year":"2001","unstructured":"Pearl, G. M., Livingston-Carr, S. & Durham, S. K. Integration of computational analysis as a sentinel tool in toxicological assessments. Curr. Top. Med. Chem. 1, 247\u2013255 (2001).","journal-title":"Curr. Top. Med. Chem."},{"key":"BFnrmicro1816_CR29","volume-title":"Annual Conference on Antimicrobial Resistance","author":"R Goldman","year":"2006","unstructured":"Goldman, R. et al. in Annual Conference on Antimicrobial Resistance (National Foundation for Infectious Diseases, Bethesda, 2006)."},{"key":"BFnrmicro1816_CR30","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/JB.182.7.1802-1811.2000","volume":"182","author":"D Alland","year":"2000","unstructured":"Alland, D., Steyn, A. J., Weisbrod, T., Aldrich, K. & Jacobs, W. R. Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182, 1802\u20131811 (2000).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro1816_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/JB.157.1.46-52.1984","volume":"157","author":"N Qureshi","year":"1984","unstructured":"Qureshi, N., Sathyamoorthy, N. & Takayama, K. Biosynthesis of C30 to C56 fatty acids by an extract of Mycobacterium tuberculosis H37Ra. J. Bacteriol. 157, 46\u201352 (1984).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro1816_CR32","doi-asserted-by":"publisher","first-page":"15582","DOI":"10.1074\/jbc.274.22.15582","volume":"274","author":"DA Rozwarski","year":"1999","unstructured":"Rozwarski, D. A., Vilch\u00e9ze, C., Sugantino, M., Bittman, R. & Sacchettini, J. C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 274, 15582\u201315589 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro1816_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/358591a0","volume":"358","author":"Y Zhang","year":"1992","unstructured":"Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591\u2013593 (1992).","journal-title":"Nature"},{"key":"BFnrmicro1816_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm1252","volume":"11","author":"EJ Mu\u00f1oz-El\u00edas","year":"2005","unstructured":"Mu\u00f1oz-El\u00edas, E. J. & McKinney, J. D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nature Med. 11, 638\u2013644 (2005).","journal-title":"Nature Med."},{"key":"BFnrmicro1816_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/77964","volume":"7","author":"V Sharma","year":"2000","unstructured":"Sharma, V. et al. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nature Struct. Biol. 7, 663\u2013668 (2000).","journal-title":"Nature Struct. Biol."},{"key":"BFnrmicro1816_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/1087057106296484","volume":"12","author":"EL White","year":"2007","unstructured":"White, E. L. et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J. Biomol. Screen. 12, 100\u2013105 (2007).","journal-title":"J. Biomol. Screen."},{"key":"BFnrmicro1816_CR37","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/jm050948+","volume":"49","author":"E Bogatcheva","year":"2006","unstructured":"Bogatcheva, E. et al. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem. 49, 3045\u20133048 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnrmicro1816_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/187152607781001853","volume":"7","author":"AC Murillo","year":"2007","unstructured":"Murillo, A. C. et al. High throughput crystallography of TB drug targets. Infect. Disord. Drug Targets 7, 127\u2013139 (2007). Discusses the use of X-ray crystallography to catalyze TB drug-discovery efforts by the elucidation of the structures of essential M. tuberculosis gene products.","journal-title":"Infect. Disord. Drug Targets"},{"key":"BFnrmicro1816_CR39","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nrd941","volume":"1","author":"J Bajorath","year":"2002","unstructured":"Bajorath, J. Integration of virtual and high-throughput screening. Nature Rev. Drug Discov. 1, 882\u2013894 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro1816_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nature03197","volume":"432","author":"BK Shoichet","year":"2004","unstructured":"Shoichet, B. K. Virtual screening of chemical libraries. Nature 432, 862\u2013865 (2004). Provides a good introduction to virtual screening using examples from drug discovery.","journal-title":"Nature"},{"key":"BFnrmicro1816_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1367-5931(02)00339-3","volume":"6","author":"BK Shoichet","year":"2002","unstructured":"Shoichet, B. K., McGovern, S. L., Wei, B. & Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6, 439\u2013446 (2002).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"BFnrmicro1816_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/cmdc.200600026","volume":"1","author":"F Manetti","year":"2006","unstructured":"Manetti, F. et al. Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of Mycobacterium tuberculosis. ChemMedChem 1, 973\u2013989 (2006).","journal-title":"ChemMedChem"},{"key":"BFnrmicro1816_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1087057104273486","volume":"10","author":"A Garc\u00eda-Garc\u00eda","year":"2005","unstructured":"Garc\u00eda-Garc\u00eda, A. et al. Search of chemical scaffolds for novel antituberculosis agents. J. Biomol. Screen. 10, 206\u2013214 (2005).","journal-title":"J. Biomol. Screen."},{"key":"BFnrmicro1816_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrmicro1816_CR45","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/j.bmcl.2007.03.053","volume":"17","author":"H Agrawal","year":"2007","unstructured":"Agrawal, H., Kumar, A., Bal, N. C., Siddiqi, M. I. & Arora, A. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett. 17, 3053\u20133058 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrmicro1816_CR46","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1099\/00221287-148-10-3069","volume":"148","author":"T Parish","year":"2002","unstructured":"Parish, T. & Stoker, N. G. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148, 3069\u20133077 (2002).","journal-title":"Microbiology"},{"key":"BFnrmicro1816_CR47","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.bmc.2004.06.037","volume":"15","author":"ME Hediger","year":"2004","unstructured":"Hediger, M. E. Design, synthesis, and evaluation of aza inhibitors of chorismate mutase. Bioorg. Med. Chem. 15, 4995\u20135010 (2004).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrmicro1816_CR48","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1073\/pnas.0510580103","volume":"103","author":"TW Lin","year":"2006","unstructured":"Lin, T. W. et al. Structure-based inhibitor design of ACCD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 3072\u20133077 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29\u201340 (2007).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrmicro1816_CR50","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.7886450","volume":"267","author":"A Dessen","year":"1995","unstructured":"Dessen, A., Quemard, A., Blanchard, J. S., Jacobs, W. R. Jr & Sacchettini, J. C. Crystal structure and function of the isoniazid target of M. tuberculosis. Science 267, 1638\u20131641 (1995).","journal-title":"Science"},{"key":"BFnrmicro1816_CR51","doi-asserted-by":"publisher","first-page":"20851","DOI":"10.1074\/jbc.M211968200","volume":"278","author":"MR Kuo","year":"2003","unstructured":"Kuo, M. R. et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J. Biol. Chem. 278, 20851\u201320859 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro1816_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.279.5347.98","volume":"279","author":"DA Rozwarski","year":"1998","unstructured":"Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R. Jr & Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98\u2013102 (1998).","journal-title":"Science"},{"key":"BFnrmicro1816_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.20062100","volume":"204","author":"F Wang","year":"2007","unstructured":"Wang, F. et al. Mechanism of thionamide drug action against tuberculosis and leprosy. J. Exp. Med. 204, 73\u201378 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrmicro1816_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1021\/cb0500042","volume":"1","author":"TJ Sullivan","year":"2006","unstructured":"Sullivan, T. J. et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1, 43\u201353 (2006).","journal-title":"ACS Chem. Biol."},{"key":"BFnrmicro1816_CR55","first-page":"352","volume":"131","author":"M Tsukamura","year":"1985","unstructured":"Tsukamura, M., Nakamura, E., Yoshii, S. & Amano, H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131, 352\u2013356 (1985).","journal-title":"Am. Rev. Respir. Dis."},{"key":"BFnrmicro1816_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","volume":"50","author":"A Aubry","year":"2006","unstructured":"Aubry, A. et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50, 104\u2013112 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10096-007-0298-0","volume":"26","author":"N Veziris","year":"2007","unstructured":"Veziris, N. et al. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur. J. Clin. Microbiol. Infect. Dis. 26, 423\u2013425 (2007).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFnrmicro1816_CR58","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537\u2013544 (1998). Determined the genome of M. tuberculosis H37Rv.","journal-title":"Nature"},{"key":"BFnrmicro1816_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1073\/pnas.93.1.362","volume":"9","author":"HE Takiff","year":"1996","unstructured":"Takiff, H. E. et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl Acad. Sci. USA 9, 362\u2013366 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jac\/dkm200","volume":"60","author":"M Cynamon","year":"2007","unstructured":"Cynamon, M., Sklaney, M. R. & Shoen, C. Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J. Antimicrob. Chemother. 60, 429\u2013432 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR61","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1086\/518663","volume":"196","author":"MK Spigelman","year":"2007","unstructured":"Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196, S28\u2013S34 (2007).","journal-title":"J. Infect. Dis."},{"key":"BFnrmicro1816_CR62","first-page":"605","volume":"30","author":"R Cricchio","year":"1975","unstructured":"Cricchio, R., Arioli, V. & Lancini, G. C. Hydrazones of 3-formylrifamycin SV. I \u2014 hydrazones with N-amino-N\u2032-substituted piperazines: synthesis, antibacterial activity and other biological properties. Farmaco [Sci] 30, 605\u2013619 (1975).","journal-title":"Farmaco [Sci]"},{"key":"BFnrmicro1816_CR63","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.7164\/antibiotics.34.1026","volume":"34","author":"V Arioli","year":"1981","unstructured":"Arioli, V. et al. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J. Antibiot. (Tokyo) 34, 1026\u20131032 (1981).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFnrmicro1816_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/jac\/46.4.571","volume":"46","author":"P Bemer-Melchior","year":"2000","unstructured":"Bemer-Melchior, P., Bryskier, A. & Drugeon, H. B. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 46, 571\u2013575 (2000).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0041-3879(87)90026-2","volume":"68","author":"JM Dickinson","year":"1987","unstructured":"Dickinson, J. M. & Mitchison, D. A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68, 113\u2013118 (1987).","journal-title":"Tubercle"},{"key":"BFnrmicro1816_CR66","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","volume":"40","author":"WJ Burman","year":"2001","unstructured":"Burman, W. J., Gallicano, K. & Peloquin, C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327\u2013341 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrmicro1816_CR67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1248\/cpb.41.148","volume":"41","author":"T Yamane","year":"1993","unstructured":"Yamane, T. et al. Synthesis and biological activity of 3\u2032-hydroxy-5\u2032-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. (Tokyo) 41, 148\u2013155 (1993).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"BFnrmicro1816_CR68","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1128\/AAC.39.7.1489","volume":"39","author":"K Fuji","year":"1995","unstructured":"Fuji, K., Saito, H., Tomioka, H., Mae, T. & Hosoe, K. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob. Agents Chemother. 39, 1489\u20131492 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR69","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1128\/AAC.39.10.2295","volume":"39","author":"T Hirata","year":"1995","unstructured":"Hirata, T. et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39, 2295\u20132303 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/AAC.40.2.298","volume":"40","author":"SP Klemens","year":"1996","unstructured":"Klemens, S. P. & Cynamon, M. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 40, 298\u2013301 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR71","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1128\/AAC.45.7.1972-1976.2001","volume":"45","author":"R Dietze","year":"2001","unstructured":"Dietze, R. et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45, 1972\u20131976 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/004982598239173","volume":"28","author":"T Mae","year":"1998","unstructured":"Mae, T. et al. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica 28, 759\u2013766 (1998).","journal-title":"Xenobiotica"},{"key":"BFnrmicro1816_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/ajrccm.164.1.2101133","volume":"164","author":"WJ Burman","year":"2001","unstructured":"Burman, W. J. & Jones, B. E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am. J. Respir. Crit. Care Med. 164, 7\u201312 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrmicro1816_CR74","unstructured":"Report No. TDR\/PRD\/TB\/03.1W (World Health Organization, Geneva, 2003)."},{"key":"BFnrmicro1816_CR75","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1021\/jm01239a017","volume":"5","author":"RG Shepherd","year":"1962","unstructured":"Shepherd, R. G. & Wilkinson, R. G. Antituberculous agents. II. N,N\u2032-diisopropylethylenediamine and analogs. J. Med. Pharm. Chem. 5, 823\u2013835 (1962).","journal-title":"J. Med. Pharm. Chem."},{"key":"BFnrmicro1816_CR76","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1021\/jm01239a018","volume":"5","author":"RG Wilkinson","year":"1962","unstructured":"Wilkinson, R. G., Cantrall, M. B. & Shepherd, R. G. Antituberculous agents. III. (+)-2,2-(ethylenediimino)-di-1-butanol and some analogs. J. Med. Pharm. Chem. 5, 835\u2013845 (1962).","journal-title":"J. Med. Pharm. Chem."},{"key":"BFnrmicro1816_CR77","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","volume":"144","author":"L Jia","year":"2005","unstructured":"Jia, L. et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80\u201387 (2005).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrmicro1816_CR78","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"A Koul","year":"2007","unstructured":"Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323\u2013324 (2007).","journal-title":"Nature Chem. Biol."},{"key":"BFnrmicro1816_CR79","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1128\/AAC.00244-06","volume":"50","author":"S Petrella","year":"2006","unstructured":"Petrella, S. et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853\u20132856 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR80","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1128\/AAC.00766-06","volume":"50","author":"N Lounis","year":"2006","unstructured":"Lounis, N. et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50, 3543\u20133547 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR81","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.42.11.3035","volume":"42","author":"D Deidda","year":"1998","unstructured":"Deidda, D. et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. 42, 3035\u20133037 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR82","unstructured":"Arora, S. K., Sinha, N., Sinha, R. & Upadhyaya, R. S.U.S. Patent Application. US 2005\/0256128 A1 (2005)."},{"key":"BFnrmicro1816_CR83","unstructured":"Casenghi, M. Development of new drugs for TB chemotherapy. Campaign for access to essential medicines [ online ], (2006)."},{"key":"BFnrmicro1816_CR84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jac\/5.5.499","volume":"5","author":"DI Edwards","year":"1979","unstructured":"Edwards, D. I. Mechanism of antimicrobial action of metronidazole. J. Antimicrob. Chemother. 5, 499\u2013502 (1979).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR85","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.micro.55.1.139","volume":"55","author":"LG Wayne","year":"2001","unstructured":"Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139\u2013163 (2001).","journal-title":"Annu. Rev. Microbiol."},{"key":"BFnrmicro1816_CR86","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1128\/AAC.38.9.2054","volume":"38","author":"LG Wayne","year":"1994","unstructured":"Wayne, L. G. & Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054\u20132058 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR87","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/AAC.43.5.1285","volume":"43","author":"JV Brooks","year":"1999","unstructured":"Brooks, J. V., Furney, S. K. & Orme, I. M. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43, 1285\u20131288 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/AAC.37.2.183","volume":"37","author":"DR Ashtekar","year":"1993","unstructured":"Ashtekar, D. R. et al. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37, 183\u2013186 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR89","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0223-5234(89)90034-2","volume":"24","author":"K Nagrajan","year":"1989","unstructured":"Nagrajan, K., Shankar, R. G., Rajappa, S., Shenoy, S. J. & Costa-Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity. Eur. J. Med. Chem. 24, 631\u2013633 (1989).","journal-title":"Eur. J. Med. Chem."},{"key":"BFnrmicro1816_CR90","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962\u2013966 (2000).","journal-title":"Nature"},{"key":"BFnrmicro1816_CR91","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","volume":"49","author":"S Tyagi","year":"2005","unstructured":"Tyagi, S. et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49, 2289\u20132293 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR92","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1128\/AAC.00451-06","volume":"50","author":"E Nuermberger","year":"2006","unstructured":"Nuermberger, E. et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50, 2621\u20132625 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR93","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, 2131\u20132144 (2006).","journal-title":"PLoS Med."},{"key":"BFnrmicro1816_CR94","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1021\/jm060957y","volume":"49","author":"H Sasaki","year":"2006","unstructured":"Sasaki, H. et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 49, 7854\u20137860 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnrmicro1816_CR95","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00436-002-0754-9","volume":"90","author":"W Raether","year":"2003","unstructured":"Raether, W. & H\u00e4nel, H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol. Res. 90, S19\u2013S39 (2003).","journal-title":"Parasitol. Res."},{"key":"BFnrmicro1816_CR96","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1021\/jm9509556","volume":"39","author":"SJ Brickner","year":"1996","unstructured":"Brickner, S. J. et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39, 673\u2013679 (1996).","journal-title":"J. Med. Chem."},{"key":"BFnrmicro1816_CR97","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1128\/AAC.40.4.839","volume":"40","author":"GE Zurenko","year":"1996","unstructured":"Zurenko, G. E. et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839\u2013845 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR98","doi-asserted-by":"publisher","first-page":"21972","DOI":"10.1074\/jbc.M302109200","volume":"278","author":"JR Colca","year":"2003","unstructured":"Colca, J. R. et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278, 21972\u201321979 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrmicro1816_CR99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jac\/dki148","volume":"56","author":"J Fort\u00fan","year":"2005","unstructured":"Fort\u00fan, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180\u2013185 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR100","first-page":"606","volume":"11","author":"F Ntziora","year":"2007","unstructured":"Ntziora, F. & Falagas, M. E. Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review. Int. J. Tuberc. Lung Dis. 11, 606\u2013611 (2007).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrmicro1816_CR101","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jac\/dkl298","volume":"58","author":"IN Park","year":"2006","unstructured":"Park, I. N. et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58, 701\u2013704 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR102","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jinf.2005.04.007","volume":"52","author":"B von der Lippe","year":"2006","unstructured":"von der Lippe, B., Sandven, P. & Brubakk, O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) \u2014 a report of ten cases. J. Infect. 52, 92\u201396 (2006).","journal-title":"J. Infect."},{"key":"BFnrmicro1816_CR103","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijantimicag.2005.01.021","volume":"25","author":"R Sood","year":"2005","unstructured":"Sood, R., Rao, M., Singhal, S. & Rattan, A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int. J. Antimicrob. Agents 25, 464\u2013468 (2005).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFnrmicro1816_CR104","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1021\/cr030102i","volume":"105","author":"JF Fisher","year":"2005","unstructured":"Fisher, J. F., Meroueh, S. O. & Mobashery, S. Bacterial resistance to \u03b2-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105, 395\u2013424 (2005).","journal-title":"Chem. Rev."},{"key":"BFnrmicro1816_CR105","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1099\/mic.0.27629-0","volume":"151","author":"AR Flores","year":"2005","unstructured":"Flores, A. R., Parsons, L. M. & Pavelka, M. S. Jr. Genetic analysis of the \u03b2-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to \u03b2-lactam antibiotics. Microbiology 151, 521\u2013532 (2005).","journal-title":"Microbiology"},{"key":"BFnrmicro1816_CR106","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1128\/AAC.00320-06","volume":"50","author":"F Wang","year":"2006","unstructured":"Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the Mycobacterium tuberculosis \u03b2-lactamase reveal its critical role in resistance to \u03b2-lactam antibiotics. Antimicrob. Agents Chemother. 50, 2762\u20132771 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR107","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1128\/JB.187.6.1892-1900.2005","volume":"187","author":"AR Flores","year":"2005","unstructured":"Flores, A. R., Parsons, L. M. & Pavelka, M. S. Jr. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to \u03b2-lactam antibiotics. J. Bacteriol. 187, 1892\u20131900 (2005).","journal-title":"J. Bacteriol."},{"key":"BFnrmicro1816_CR108","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/AAC.39.12.2620","volume":"39","author":"HF Chambers","year":"1995","unstructured":"Chambers, H. F. et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39, 2620\u20132624 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR109","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","volume":"49","author":"HF Chambers","year":"2005","unstructured":"Chambers, H. F., Turner, J., Schecter, G. F., Kawamura, M. & Hopewell, P. C. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49, 2816\u20132821 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR110","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/jac\/dkl354","volume":"58","author":"AC Rodloff","year":"2006","unstructured":"Rodloff, A. C., Goldstein, E. J. C. & Torres, A. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58, 916\u2013929 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR111","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1086\/513945","volume":"26","author":"HF Chambers","year":"1998","unstructured":"Chambers, H. F., Kocagoz, S., Sipit, T., Turner, J. & Hopewell, P. C. Activity of amoxicillin\/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26, 874\u2013877 (1998).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrmicro1816_CR112","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1128\/AAC.01226-05","volume":"50","author":"E Sauvage","year":"2006","unstructured":"Sauvage, E. et al. Crystal structure of the Mycobacterium fortuitum class A \u03b2-lactamase: structural basis for broad substrate specificity. Antimicrob. Agents Chemother. 50, 2516\u20132521 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR113","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10401230591002002","volume":"17","author":"F Lopez-Munoz","year":"2006","unstructured":"Lopez-Munoz, F. et al. History of the discovery and clinical introduction of chlorpromazine. Ann. Clin. Psychiatry 17, 113\u2013135 (2006).","journal-title":"Ann. Clin. Psychiatry"},{"key":"BFnrmicro1816_CR114","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jac\/47.5.505","volume":"47","author":"L Amaral","year":"2001","unstructured":"Amaral, L., Kristiansen, J. E., Viveiros, M. & Atouguia, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47, 505\u2013511 (2001).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR115","first-page":"562","volume":"81","author":"LE Hollister","year":"1960","unstructured":"Hollister, L. E., Eikenberry, D. T. & Raffel, S. Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 81, 562\u2013566 (1960).","journal-title":"Am. Rev. Respir. Dis."},{"key":"BFnrmicro1816_CR116","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jac\/38.6.1049","volume":"38","author":"L Amaral","year":"1996","unstructured":"Amaral, L., Kristiansen, J. E., Abebe, L. S. & Millet, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38, 1049\u20131053 (1996).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1574-6968.1992.tb05442.x","volume":"1","author":"P Ratnakar","year":"1992","unstructured":"Ratnakar, P. & Murthy, P. S. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol. Lett. 1, 73\u201376 (1992).","journal-title":"FEMS Microbiol. Lett."},{"key":"BFnrmicro1816_CR118","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jac\/37.1.196","volume":"37","author":"MV Reddy","year":"1996","unstructured":"Reddy, M. V., Nadadhur, G. & Gangadharam, P. R. In-vitro and intracellular antimycobacterial activity of trifluoperazine. J. Antimicrob. Chemother. 37, 196\u2013197 (1996).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR119","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000239036","volume":"38","author":"AJ Crowle","year":"1992","unstructured":"Crowle, A. J., Douvas, G. S. & May, M. H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 38, 410\u2013419 (1992).","journal-title":"Chemotherapy"},{"key":"BFnrmicro1816_CR120","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","volume":"47","author":"D Ordway","year":"2003","unstructured":"Ordway, D. et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 917\u2013922 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR121","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.0500469102","volume":"102","author":"EA Weinstein","year":"2005","unstructured":"Weinstein, E. A. et al. Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl Acad. Sci. USA 102, 4548\u20134553 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro1816_CR122","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1128\/AAC.49.11.4778-4780.2005","volume":"49","author":"Z Xie","year":"2005","unstructured":"Xie, Z., Siddiqi, N. & Rubin, E. J. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 49, 4778\u20134780 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrmicro1816_CR123","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.bmcl.2006.11.091","volume":"17","author":"AB Bate","year":"2007","unstructured":"Bate, A. B. et al. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg. Med. Chem. Lett. 17, 1346\u20131348 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrmicro1816_CR124","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1016\/j.bmcl.2007.03.064","volume":"17","author":"PB Madrid","year":"2007","unstructured":"Madrid, P. B., Polgar, W. E., Toll, L. & Tanga, M. J. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg. Med. Chem. Lett. 17, 3014\u20133017 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrmicro1816_CR125","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3181\/00379727-55-14461","volume":"55","author":"A Schatz","year":"1944","unstructured":"Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66\u201369 (1944).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrmicro1816_CR126","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3181\/00379727-57-14769","volume":"57","author":"A Schatz","year":"1944","unstructured":"Schatz, A., Bugie, E. & Waksman, S. A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc. Soc. Exp. Biol. Med. 57, 244\u2013248 (1944).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrmicro1816_CR127","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jhmas\/jri040","volume":"60","author":"W Kingston","year":"2005","unstructured":"Kingston, W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J. Hist. Med. Allied Sci. 60, 218\u2013220 (2005).","journal-title":"J. Hist. Med. Allied Sci."},{"key":"BFnrmicro1816_CR128","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF chimera \u2014 a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"BFnrmicro1816_CR129","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jac\/46.5.669","volume":"46","author":"DH Wright","year":"2000","unstructured":"Wright, D. H., Brown, G. H., Peterson, M. L. & Rotschafer, J. C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46, 669\u2013683 (2000).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrmicro1816_CR130","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","volume":"50","author":"H McIlleron","year":"2006","unstructured":"McIlleron, H. et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents. Chemother. 50, 1170\u20131177 (2006).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"BFnrmicro1816_CR131","first-page":"663","volume-title":"Antimicrobial Chemotherapy","author":"SE Berning","year":"1998","unstructured":"Berning, S. E. & Peloquin, C. A. in Antimicrobial Chemotherapy (eds Yu, V. L., Merigan, T. C., Barriere, S. & White, N. J.) 663\u2013668 (Williams and Wilkins, Maryland, 1998)."},{"key":"BFnrmicro1816_CR132","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF01062351","volume":"1","author":"JT Doluisio","year":"1973","unstructured":"Doluisio, J. T., Dittert, L. W. & LaPiana, J. C. Pharmacokinetics of kanamycin following intramuscular administration. J. Pharmacokinet. Biopharm. 1, 253\u2013265 (1973).","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"BFnrmicro1816_CR133","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2003.07.001","volume":"23","author":"G Adamis","year":"2004","unstructured":"Adamis, G. et al. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Int. J. Antimicrob. Agents 23, 144\u2013149 (2004).","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrmicro1816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro1816","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro1816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:23:52Z","timestamp":1684470232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrmicro1816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["BFnrmicro1816"],"URL":"https:\/\/doi.org\/10.1038\/nrmicro1816","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}